<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00703313</url>
  </required_header>
  <id_info>
    <org_study_id>VPH0108</org_study_id>
    <nct_id>NCT00703313</nct_id>
  </id_info>
  <brief_title>Ocular Availability in Human Tears After Topical Administration of 1.5% Levofloxacin Compared to Active Comparators</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Santen Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Santen Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to compare the concentration in human tears of
      levofloxacin and the active comparators at 15 minutes, 2,6, 12, and 24 hours after
      instillation of a single drop of medication.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration of levofloxacin, moxifloxacin or gatifloxacin in tears</measure>
    <time_frame>15 minutes, 2, 6, 12 and 24 hours</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>described in intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>described in intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>described in intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1.5% levofloxacin ophthalmic solution</intervention_name>
    <description>1 drop instilled at each visit</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.5% moxifloxacin hydrochloride ophthalmic solution</intervention_name>
    <description>1 drop instilled at each visit</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.3% gatifloxacin ophthalmic solution</intervention_name>
    <description>1 drop instilled at each visit</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be willing and able to provide written informed consent and HIPAA indicating that they
             understand the purpose of and procedures required for the study and are willing to
             participate in the study

          -  Be willing and able to follow all instructions and attend all study visits

          -  If female and of childbearing potential, not be pregnant, nursing or planning a
             pregnancy and agree to submit to a pregnancy test. The result of the test must be
             negative and female subjects of childbearing potential must also agree to use an
             acceptable method of contraception for the duration of the study (acceptable method of
             contraception includes oral, implantable, transdermal, or injectible contraceptives,
             spermicide with barrier, IUD, or surgical sterilization of partner)

        Exclusion Criteria:

          -  Have a known allergy and/or sensitivity to the test article(s) or its components or
             any therapies associated with the study

          -  Have active signs or symptoms of any clinically significant ocular disorder (other
             than refractive disorders)

          -  Have a history of dry eye syndrome

          -  Use disallowed medications (systemic or topical) (i.e. any fluoroquinolone
             anti-infective agents or any topical ophthalmic products) during the appropriate
             pre-study washout period and during the study.

          -  Be a contact lens wearer who is unwilling to forego contact lens wear within 3 days
             prior to the start of the study and for the duration of the study

          -  Have had any ocular surgical intervention 12 months prior to the study or anticipate
             having ocular surgery during the study

          -  Be pregnant or nursing women; or women who have a positive urine pregnancy test at
             screening or women of childbearing potential who refuse to use an adequate hormonal or
             mechanical means of birth control

          -  Be concurrently enrolled in an investigational drug or device study or have used an
             investigational drug or device within 30 days of entry into this study

          -  Employees of the investigator or study center, with direct involvement in th proposed
             study or other studies under the direction of that investigator or study center, as
             well as family members of the employees or the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Vistakon</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2008</study_first_submitted>
  <study_first_submitted_qc>June 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2008</study_first_posted>
  <last_update_submitted>February 4, 2009</last_update_submitted>
  <last_update_submitted_qc>February 4, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2009</last_update_posted>
  <responsible_party>
    <name_title>Brian Schwam, MD/Medical Director</name_title>
    <organization>VISTAKON Pharmaceuticals</organization>
  </responsible_party>
  <keyword>Study drug concentration in human tears</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
    <mesh_term>Gatifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>June 30, 2009</submitted>
    <returned>August 12, 2009</returned>
    <submitted>September 23, 2009</submitted>
    <returned>October 13, 2009</returned>
    <submitted>June 17, 2010</submitted>
    <returned>July 13, 2010</returned>
    <submitted>April 17, 2012</submitted>
    <returned>May 15, 2012</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

